首页>投融资
Alumis
上市
Alumis, formerly known as Esker Therapeutics (previously FL2021-001), is focused on developing precision medicines for the potential treatment of autoimmune diseases.In January 2022, the company changed its name from Esker Therapeutics to Alumis
基本信息
-
公司全称Alumis Inc
-
类型自身免疫性疾病疗法研发商
-
产业领域药品研发/制造、生物/化学技术
-
公司人数101~500人
-
地址611 Gateway Blvd. Suite 820 SOUTH SAN FRANCISCO CALIFORNIA 94080; US;
-
联系电话1-650-2316625
-
邮箱info@alumis.com
-
成立时间2021-01-01
投融资
-
2024-06-28上市2.5亿美元未透露
-
2024-03-06C轮2.59亿美元Foresite CapitalSamsara BioCapitalVenBio Partners鱼鹰资管SR One礼来亚洲基金Nextech Invest汇桥资本HBM HealthcareOmega FundsAyurMaya
-
2022-01-06B轮2亿美元AyurMaya
-
2021-05-05A轮7000万美元Foresite Capital
- 加载更多
相关投融资企业
A轮
LoQus23 is a Dementia Discovery Fund formed company focussing on targeting DNA damage repair pathways to treat Huntington’s disease.In November 2021, LoQus23 Therapeutics Ltd announced the successful closing of its £7 million extended seed round
上市
OS Therapies (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS).In November 2020, OS Therapies announced the acquisition of all indications for OST-HER2 including Canine.In June 2021 Advaxis Inc licensing agreement with OS Therapies.In April 2021, OS Therapies announced the closing of a $6 million Series A round of funding
上市
Alumis, formerly known as Esker Therapeutics (previously FL2021-001), is focused on developing precision medicines for the potential treatment of autoimmune diseases.In January 2022, the company changed its name from Esker Therapeutics to Alumis
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息